We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. Supreme Court on Friday weighed in on the debate over access to the abortion pill mifepristone, permitting a stay sought by the Department of Justice earlier this month and adding a layer of complexity to an already tangled tale of drug approval and access. Read More
The FDA Office of Prescription Drug Promotion (OPDP) is seeking input on its proposal to conduct research into how consumers interpret certain quantitative information about prescription drugs often included in direct-to-consumer (DTC) advertising. Read More
Bluebird Bio is pulling out all the regulatory stops for its investigational sickle cell disease (SCD) gene therapy lovotibeglogene autotemcel (lovo-cel), submitting a BLA with a request for priority review in addition to the four expedited approval designations the FDA had already granted the drug. Read More
The European Medicines Agency (EMA) has become the first regulator to accept the International Council for Harmonization (ICH) S12 guideline, laying out the council’s recommendations for how to conduct nonclinical biodistribution (BD) studies when developing gene therapy products. Read More
More than half of the best-selling brand-name drugs covered by Medicare may not provide significant added therapeutic benefits despite comprising a large portion of the federal agency’s spending, according to results of a study published in JAMA Network this week. Read More
Over the past week, the FDA issued a correction of a docket, an authorization and two revocations of diagnostic devices and a request for comments on rapid response surveys. In addition, the agency announced a public workshop. Read More
mRNA developer Moderna and computer giant IBM have announced an agreement under which Moderna will explore next-generation technologies, including quantum computing and artificial intelligence (AI), to accelerate mRNA research and science. Read More
GenBioPro, the only U.S. maker of the generic version of the abortion pill mifepristone, has sued the FDA, HHS and DOJ in an effort to protect the company from regulatory action that could withdraw or limit FDA approval of its drug based on recent court rulings. Read More
The FDA’s latest proposed trial design for evaluating the effectiveness of opioids as chronic pain treatments was met with backlash from pain management and anesthesiology experts who contend the protocol is flawed on multiple fronts. Read More